Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.Background reading:
Photo: Sergei Gapon/Agence France-Presse — Getty ImagesFor more information on today’s episode, visit
nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Subscribe today at
nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here
https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.
Hosted by Simplecast, an AdsWizz company. See
pcm.adswizz.com for information about our collection and use of personal data for advertising.
“Educational Disclaimer: This episode is presented as part of an independent archival project dedicated to media literacy and the preservation of modern journalism. The content is curated for academic reference, linguistic study, and socio-economic research purposes. All original rights belong to the respective content creators. Our mission is to provide high-fidelity accessibility and full AI-generated transcripts for students of global discourse and international relations in the 2026 digital era"
